Top 10 Early Stage Investors: Biotechnology, Pharma & Life Sciences
| Rank | Investor Name |
|---|---|
| 1 | RA Capital Management |
| 2 | ORBIMED Healthcare Fund Management |
| 3 | ARCH Venture Partners |
| 4 | Camden Partners |
| 5 | Eli Lilly and Company |
| 6 | Even One Ventures |
| 7 | Frazier Healthcare Partners |
| 8 | Atlas Ventures |
| 9 | Andreessen Horowitz - a16z |
| 10 | BVF Partners |
Early stage activity in this category is led by institutional venture franchises and category specialists. Platform science and pharma partnership appetite drive the category, with specialist funds leading most rounds. For a company raising a priced early round, this list identifies the firms with the most active recent presence in the category.
The CapitalDart directory identifies the right person to contact at each of these firms, with their individual investment criteria.
Rankings reflect investment activity from January 2025 through July 2026 in US and Canada companies, based on transactions matched to the CapitalDart directory. Seed and Early Stage rank by participation, Later Stage by rounds led, Private Equity by control and buyout activity. Updated periodically.